Register entry
- Registered sites
- 0
- Active NDC listings
- 26
- Live patents
- 59
- Exclusivities
- 3
- Shortage listings
- 1
- Countries
- 0
Alert
Drug shortage listings
1| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Maraviroc SolutionAntiviral | Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton (NDC 49702-260-55) | To Be Discontinued | - | 20 Jan 202620 Jan 2026 |
Catalogue
Drug listings by form and route
2626 active NDC listings: 26 human prescription drug. By marketing category: NDA 26.
| Dosage form | NDCs |
|---|---|
| tablet, film coated | 12 |
| kit | 7 |
| solution | 3 |
| capsule | 1 |
| injection, solution | 1 |
| tablet, film coated, extended release | 1 |
| tablet, for suspension | 1 |
| Route | NDCs |
|---|---|
| oral | 18 |
| intravenous | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| viiv healthcare company | 26 |
Exclusivity
Patents and exclusivities
59| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 11389447 | CABENUVA KITcabotegravir; rilpivirine | use | Jun 2027 |
| 8129385 | DOVATO, JULUCA, TIVICAY, TIVICAY PD, TRIUMEQ, TRIUMEQ PDabacavir sulfate; dolutegravir sodium; lamivudine; dolutegravir sodium; dolutegravir sodium; lamivudine; dolutegravir sodium; rilpivirine hydrochloride | substance, product | Oct 2027 |
| 7745625 | RUKOBIAfostemsavir tromethamine | substance | Nov 2027 |
| 8129385*PED | DOVATO, JULUCA, TIVICAY, TIVICAY PD, TRIUMEQ, TRIUMEQ PDabacavir sulfate; dolutegravir sodium; lamivudine; dolutegravir sodium; dolutegravir sodium; lamivudine; dolutegravir sodium; rilpivirine hydrochloride | use | Apr 2028 |
| 8168615 | RUKOBIAfostemsavir tromethamine | product | Jul 2029 |
| 9242986 | DOVATO, JULUCA, TIVICAY, TIVICAY PD, TRIUMEQ, TRIUMEQ PDabacavir sulfate; dolutegravir sodium; lamivudine; dolutegravir sodium; dolutegravir sodium; lamivudine; dolutegravir sodium; rilpivirine hydrochloride | substance, product | Dec 2029 |
| 9242986*PED | DOVATO, JULUCA, TIVICAY, TIVICAY PD, TRIUMEQ, TRIUMEQ PDabacavir sulfate; dolutegravir sodium; lamivudine; dolutegravir sodium; dolutegravir sodium; lamivudine; dolutegravir sodium; rilpivirine hydrochloride | use | Jun 2030 |
| 10426780 | JULUCAdolutegravir sodium; rilpivirine hydrochloride | substance, product | Jan 2031 |
| 11234985 | DOVATOdolutegravir sodium; lamivudine | product | Jan 2031 |
| 8410103 | APRETUDE, CABENUVA KIT, VOCABRIAcabotegravir; cabotegravir sodium; cabotegravir; rilpivirine | substance, product | Feb 2031 |
| 11224597 | APRETUDE, CABENUVA KITcabotegravir; cabotegravir; rilpivirine | product | Sept 2031 |
| 12138264 | APRETUDE, CABENUVA KITcabotegravir; cabotegravir; rilpivirine | product | Sept 2031 |
| RE50189 | CABENUVA KITcabotegravir; rilpivirine | use | Nov 2031 |
| 11389448 | CABENUVA KITcabotegravir; rilpivirine | product | Apr 2032 |
| 12178815 | CABENUVA KITcabotegravir; rilpivirine | use | Jul 2038 |
| 12011506 | JULUCAdolutegravir sodium; rilpivirine hydrochloride | product | Sept 2038 |
| 12636285 | CABENUVA KITcabotegravir; rilpivirine | use | Oct 2040 |
| 12636286 | CABENUVA KITcabotegravir; rilpivirine | use | Oct 2040 |
| Product | Exclusivity | Until |
|---|---|---|
| DOVATODOLUTEGRAVIR SODIUM; LAMIVUDINE | NPP New patient population | Apr 2027 |
| TRIUMEQABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE | PED Paediatric | Dec 2026 |
| TRIUMEQ PDABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE | PED Paediatric | Dec 2026 |
Catalogue
Marketed products
26| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Apretude | Cabotegravir | kit | 49702-264NDA |
| Apretude | Cabotegravir | kit | 49702-280NDA |
| COMBIVIR | lamivudine and zidovudine | tablet, film coated, oral | 49702-202NDA |
| Cabenuva | cabotegravir and rilpivirine | kit | 49702-240NDA |
| Cabenuva | cabotegravir and rilpivirine | kit | 49702-253NDA |
| Cabenuva | cabotegravir and rilpivirine | kit | 49702-266NDA |
| Dovato | dolutegravir sodium and lamivudine | tablet, film coated, oral | 49702-246NDA |
| EPIVIR | lamivudine | tablet, film coated, oral | 49702-203NDA |
| EPIVIR | lamivudine | tablet, film coated, oral | 49702-204NDA |
| EPIVIR | lamivudine | solution, oral | 49702-205NDA |
| Juluca | dolutegravir sodium and rilpivirine hydrochloride | tablet, film coated, oral | 49702-242NDA |
| RETROVIR | zidovudine | capsule, oral | 49702-211NDA |
| RETROVIR | zidovudine | solution, oral | 49702-212NDA |
| RETROVIR | zidovudine | injection, solution, intravenous | 49702-213NDA |
| Rukobia | fostemsavir tromethamine | tablet, film coated, extended release, oral | 49702-250NDA |
| SELZENTRY | maraviroc | tablet, film coated, oral | 49702-223NDA |
| SELZENTRY | maraviroc | tablet, film coated, oral | 49702-224NDA |
| SELZENTRY | maraviroc | kit | 49702-260NDA |
| Tivicay | dolutegravir sodium | tablet, film coated, oral | 49702-226NDA |
| Tivicay | dolutegravir sodium | tablet, film coated, oral | 49702-227NDA |
| Tivicay | dolutegravir sodium | tablet, film coated, oral | 49702-228NDA |
| Tivicay PD | dolutegravir sodium | tablet, for suspension, oral | 49702-255NDA |
| Triumeq | abacavir sulfate, dolutegravir sodium, lamivudine | tablet, film coated, oral | 49702-231NDA |
| Triumeq PD | abacavir sulfate, dolutegravir sodium, lamivudine | kit | 49702-258NDA |
| Vocabria | cabotegravir sodium | tablet, film coated, oral | 49702-248NDA |
| ZIAGEN | abacavir sulfate | solution, oral | 49702-222NDA |
Compare
Other companies listing dolutegravir sodium
- St. Mary's Medical Park Pharmacy1 site · 273 NDC
- Glaxo Operations UK Ltd0 sites · 31 NDC
- Glaxo Wellcome Manufacturing Pte. Ltd0 sites · 13 NDC
Enquiry
Common questions
- Is ViiV Healthcare Company FDA approved?
- ViiV Healthcare Company holds no registered establishment of its own; 26 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does ViiV Healthcare Company make?
- 26 products are listed under ViiV Healthcare Company in the openFDA NDC Directory, most often as tablet, film coated; kit; solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.